An Open Label Single Arm Phase I/II Study of MTX110 Delivered by Convection-enhanced Delivery (CED) in Patients With Diffuse Intrinsic Pontine Glioma (DIPG) Previously Treated With External Beam Radiation Therapy
Phase of Trial: Phase I/II
Latest Information Update: 27 Jun 2018
At a glance
- Drugs MTX 110 (Primary)
- Indications Glioma
- Focus Adverse reactions; First in man
- 25 May 2018 Status changed from planning to recruiting, according to a Midatech Pharma US media release.
- 25 May 2018 According to a Midatech Pharma US media release, the company has commenced dosing in this trial. The Phase I safety component of the study is expected to read out in the second half of 2019 and the Phase II efficacy component is expected to read out in 2020.
- 17 Jan 2018 New trial record